Remus Pharmaceuticals Limited — Updates, 17-05-2025: Press Release

Remus Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. FY25 revenue surged 191% YoY to INR 620.36 Cr, with EBITDA up 59% at INR 50.67 Cr and PAT increasing 58% to INR 38.42 Cr (29.07 Cr after minority interest). H2 revenue rose 27.5% over H1, driven by new market entries including Saudi Arabia and multiple product registrations. Commercializing 10+ off-patent niche products and expanding its global brand portfolio underline strong growth and strategic expansion.